Brought to you by 
Ionix and Xenome in analgesic drug discovery deal
27 Apr 2021
Executive Summary
UK analgesic drug company Ionix Pharmaceuticals and Australian Xenome (toxin peptide chemistry and drug discovery) will design, synthesize, and screen toxins (and derivatives) for their potential as inhibitors of targets that Ionix provides. The companies aim to develop and market drugs to manage chronic inflammatory and neuropathic pain.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ionix and Xenome in analgesic drug discovery deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice